Posted by Michael Wonder on 18 Nov 2024
AbbVie receives European Commission approval of Elahere (mirvetuximab soravtansine) for the treatment of platinum resistant ovarian cancer
18 November 2024 - VENTANA FOLR RxDx assay, the companion diagnostic to identify ovarian cancer patients eligible for Elahere, also receives CE Mark.
AbbVie today announced the European Commission granted marketing authorisation for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor alpha positive, platinum resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
